Browse the corpus

REFERENCES Atkins MB, Hsu J, Lee S, et al, “Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group,” J Clin Oncol , 2008, 26(35):5748-54. [PubMed 19001327 ] Atkins MB, Lotze MT, Dutcher JP, et al, “High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993,” J Clin Oncol , 1999, 17(7):2105-16. [PubMed 10561265 ] Bergmann L, Heil G, Kolbe K, et al, “Interleukin-2 Bolus Infusion as Late Consolidation Therapy in 2nd Remission of Acute Myeloblastic Leukemia,” Leuk Lymphoma , 1995, 16(3-4):271-9. [PubMed 7719235 ] Bernstein ZP, Porter MM, Gould M, et al, “Prolonged Administration of Low-Dose Interleukin-2 in Human Immunodeficiency Virus-Associated Malignancy Results in Selective Expansion of Innate Immune Effectors Without Significant Clinical Toxicity,” Blood , 1995, 86(9):3287-94. [PubMed 7579429 ] Eton O, Legha SS, Bedikian AY, et al, “Sequential Biochemotherapy Versus Chemotherapy for Metastatic Melanoma: Results From a Phase III Randomized Trial,” J Clin Oncol , 2002, 20(8):2045-52. [PubMed 11956264 ] Klapper JA, Downey SG, Smith FO, et al, “High-Dose Interleukin-2 for the Treatment of Metastatic Renal Cell Carcinoma: A Retrospective Analysis of Response and Survival in Patients Treated in the Surgery Branch at the National Cancer Institute Between 1986 and 2006,” Cancer , 2008, 113(2):293-301. [PubMed 18457330 ] Lange BJ, Smith FO, Feusner J, et al, “Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for Untreated Pediatric Acute Myeloid Leukemia: a Report From the Children's Oncology Group,” Blood , 2008, 111(3):1044-53. [PubMed 18000167 ] Legha SS, Ring S, Eton O, et al, “Development of a Biochemotherapy Regimen With Concurrent Administration of Cisplatin, Vinblastine, Dacarbazine, Interferon Alfa, and Interleukin-2 for Patients With Metastatic Melanoma,” J Clin Onco l, 1998, 16(5):1752-9. [PubMed 9586888 ]

Lange BJ, Smith FO, Feusner J, et al, “Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for Untreated Pediatric Acute Myeloid Leukemia: a Report From the Children's Oncology Group,” Blood , 2008, 111(3):1044-53. [PubMed 18000167 ] Legha SS, Ring S, Eton O, et al, “Development of a Biochemotherapy Regimen With Concurrent Administration of Cisplatin, Vinblastine, Dacarbazine, Interferon Alfa, and Interleukin-2 for Patients With Metastatic Melanoma,” J Clin Onco l, 1998, 16(5):1752-9. [PubMed 9586888 ] McDermott DF, Regan MM, Clark JI, et al, “Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma,” J Clin Oncol , 2005, 23(1):133-41. [PubMed 15625368 ] National Comprehensive Cancer Network® (NCCN), “Clinical Practice Guidelines in Oncology™: Kidney Cancer,” Version 2.2010. Available at file://www.nccn.org/professionals/physician_gls/PDF/kidney.pdf National Comprehensive Cancer Network® (NCCN), “Clinical Practice Guidelines in Oncology™: Melanoma,” Version 1.2010. Available at file://www.nccn.org/professionals/physician_gls/PDF/melanoma.pdf National Institute for Occupational Safety and Health (NIOSH), "NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012." Available at file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf . Accessed January 21, 2013. Smith FO, Downey SG, Klapper JA, et al, “Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction With Vaccines,” Clin Cancer Res , 2008, 14(17):5610-8. [PubMed 18765555 ] Yang JC, Sherry RM, Steinberg, SM, et al, “Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer,” J Clin Oncol , 2003, 21(16): 3127-32. [PubMed 12915604 ] Topic 9413 Version 42.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.6- C21.56 Licensed to: AsanBook Dig. Med. Lib. | Support Tag: [1004-218.7.204.208-7855FF150B-S244013.14]